Previous 10 | Next 10 |
2024-03-26 13:34:38 ET Summary Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportuni...
A look at the top 10 most actives in the United States C3is Inc. (CISS) rose 50.9% to $0.0531 on volume of 188,520,681 shares OpGen Inc. (OPGN) rose 64.8% to $0.783 on volume of 46,448,042 shares KULR Technology Group Inc. (KULR) rose 26.2% to $0.4102 on volume of 30,163,025 shares Tesl...
2024-03-26 08:54:38 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~20% premarket Tuesday after the company said its experimental oral therapy PRAX-628 led to a 100% complete response in a mid-stage trial for patients with photo paroxysmal response, a characteristic of epi...
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures P...
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Pr...
2024-03-06 13:06:02 ET More on Praxis Precision Medicines Praxis Precision Medicines falls after pricing of $150M equity offering Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines GAAP EPS of -$2.97 misses by $0.92, revenu...
2024-03-05 11:12:10 ET More on Praxis Precision Medicines Biggest stock movers today: Hertz Global, Crypto-linked stocks, Southwestern Energy, and more Praxis Precision Medicines falls after pricing of $150M equity offering Seeking Alpha’s Quant Rating on Prax...
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...